Open Access. Powered by Scholars. Published by Universities.®
Physical Sciences and Mathematics Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 19 of 19
Full-Text Articles in Physical Sciences and Mathematics
A Novel Peptide Inhibitor Of The Polymerization Of Deoxygenated Sickle Cell Hemoglobin, Brian Brennan, Timothy Broederdorf, '15
A Novel Peptide Inhibitor Of The Polymerization Of Deoxygenated Sickle Cell Hemoglobin, Brian Brennan, Timothy Broederdorf, '15
Brian B. Brennan
No abstract provided.
Possible New Therapeutic Treatment For Sickle Cell Disease, Brian Brennan, Ben Becker, '14
Possible New Therapeutic Treatment For Sickle Cell Disease, Brian Brennan, Ben Becker, '14
Brian B. Brennan
No abstract provided.
The Development Of A Novel Therapeutic For The Treatment Of Sickle Cell Disease, Brian Brennan, Cody Wynn, '14
The Development Of A Novel Therapeutic For The Treatment Of Sickle Cell Disease, Brian Brennan, Cody Wynn, '14
Brian B. Brennan
No abstract provided.
Fluorescent Studies Of Peptidic Hemoglobin Binding Ligands, Brian Brennan, Chris Brackett, '11
Fluorescent Studies Of Peptidic Hemoglobin Binding Ligands, Brian Brennan, Chris Brackett, '11
Brian B. Brennan
No abstract provided.
Solid-Phase Peptide Synthesis, Brian Brennan, Elisabeth Sonta, '13
Solid-Phase Peptide Synthesis, Brian Brennan, Elisabeth Sonta, '13
Brian B. Brennan
No abstract provided.
The Synthesis Of A Cyclic Peptide Library For The Discovery Of Sickle-Cell Hemoglobin Ligands, Brian Brennan, Jeremy Henle, '11
The Synthesis Of A Cyclic Peptide Library For The Discovery Of Sickle-Cell Hemoglobin Ligands, Brian Brennan, Jeremy Henle, '11
Brian B. Brennan
No abstract provided.
Homologation Of Α-Amino Acids To Β-Amino Acids Via A Modified Arndt-Eistert Synthesis, Brian Brennan, James Carolan, '10
Homologation Of Α-Amino Acids To Β-Amino Acids Via A Modified Arndt-Eistert Synthesis, Brian Brennan, James Carolan, '10
Brian B. Brennan
No abstract provided.
Utilizing Phage Display To Identify Novel Peptides That Bind To Sickle Cell Hemoglobin, Brian Brennan, Chris Betzle, '10
Utilizing Phage Display To Identify Novel Peptides That Bind To Sickle Cell Hemoglobin, Brian Brennan, Chris Betzle, '10
Brian B. Brennan
No abstract provided.
The Development Of A Novel Therapeutic For The Treatment Of Sickle Cell Disease, Brian Brennan, Steven Sturlis, '10
The Development Of A Novel Therapeutic For The Treatment Of Sickle Cell Disease, Brian Brennan, Steven Sturlis, '10
Brian B. Brennan
No abstract provided.
Novel Therapeutics In The Treatment Of Sickle Cell Disease: Expression And Purification Of Hemoglobin And Sickle Cell Hemoglobin, Brian Brennan, Susan Zhong, '11
Novel Therapeutics In The Treatment Of Sickle Cell Disease: Expression And Purification Of Hemoglobin And Sickle Cell Hemoglobin, Brian Brennan, Susan Zhong, '11
Brian B. Brennan
No abstract provided.
Utilizing Phage Display To Identify Novel Peptides That Bind To Sickle Cell Hemoglobin, Brian Brennan, Chris Betzle, '10
Utilizing Phage Display To Identify Novel Peptides That Bind To Sickle Cell Hemoglobin, Brian Brennan, Chris Betzle, '10
Brian B. Brennan
No abstract provided.
The Synthesis And Characterization Of A Peptide Hemoglobin Ligand, Brian Brennan, Chris Brackett, '11
The Synthesis And Characterization Of A Peptide Hemoglobin Ligand, Brian Brennan, Chris Brackett, '11
Brian B. Brennan
No abstract provided.
The Synthesis Of A Peptoid For Use As A Novel Therapeutic In The Treatment Of Sickle-Cell Disease, Brian Brennan, Michael Chiodo, '11
The Synthesis Of A Peptoid For Use As A Novel Therapeutic In The Treatment Of Sickle-Cell Disease, Brian Brennan, Michael Chiodo, '11
Brian B. Brennan
No abstract provided.
Amphipathic Small Molecules Mimic The Binding Mode And Function Of Endogenous Transcription Factors, Brian Brennan, Sara Buhrlage, Caleb Bates, Steven Rowe, Aaron Minter, Chinmay Majmudar, David Wemmer, Hashim Al-Hashimi, Anna Map
Amphipathic Small Molecules Mimic The Binding Mode And Function Of Endogenous Transcription Factors, Brian Brennan, Sara Buhrlage, Caleb Bates, Steven Rowe, Aaron Minter, Chinmay Majmudar, David Wemmer, Hashim Al-Hashimi, Anna Map
Brian B. Brennan
Small molecules that reconstitute the binding mode(s) of a protein and in doing so elicit a programmed functional response offer considerable advantages in the control of complex biological processes. The development challenges of such molecules are significant, however. Many protein–protein interactions require multiple points of contact over relatively large surface areas. More significantly, several binding modes can be superimposed upon a single sequence within a protein, and a true small molecule replacement must be preprogrammed for such multimodal binding. This is the case for the transcriptional activation domain or TAD of transcriptional activators as these motifs utilize a poorly characterized …
The Development Of Novel Therapeutics For Sickle-Cell Disease, Brian Brennan, Sara Costello, '10, Steven Sturlis, '10
The Development Of Novel Therapeutics For Sickle-Cell Disease, Brian Brennan, Sara Costello, '10, Steven Sturlis, '10
Brian B. Brennan
No abstract provided.
The Expression Of Recombinant Hemoglobin In Escherichia Coli, Brian Brennan, Christopher Miedema, '10, Evan Mason, '10
The Expression Of Recombinant Hemoglobin In Escherichia Coli, Brian Brennan, Christopher Miedema, '10, Evan Mason, '10
Brian B. Brennan
No abstract provided.
Unraveling The Mechanism Of A Potent Transcriptional Activator, Brian Brennan, Zhen Lu, Steven Rowe, Sarah Davis, Renee Metzler, Johnathan Nau, Chinmay Majmudar, Anna Mapp, Aseem Ansari
Unraveling The Mechanism Of A Potent Transcriptional Activator, Brian Brennan, Zhen Lu, Steven Rowe, Sarah Davis, Renee Metzler, Johnathan Nau, Chinmay Majmudar, Anna Mapp, Aseem Ansari
Brian B. Brennan
Despite their enormous potential as novel research tools and therapeutic agents, artificial transcription factors (ATFs) that up-regulate transcription robustly in vivo remain elusive. In investigating an ATF that does function exceptionally well in vivo, we uncovered an unexpected relationship between transcription function and a binding interaction between the activation domain and an adjacent region of the DNA binding domain. Disruption of this interaction leads to complete loss of function in vivo, even though the activation domain is still able to bind to its target in the transcriptional machinery. We propose that this interaction parallels those between natural activation domains and …
Stereochemical Promiscuity In Artificial Transcriptional Activators, Brian Brennan, Sara Buhrlage, Aaron Minter, Anna Mapp
Stereochemical Promiscuity In Artificial Transcriptional Activators, Brian Brennan, Sara Buhrlage, Aaron Minter, Anna Mapp
Brian B. Brennan
Small molecule replacements of transcriptional activation domains are highly desirable targets due to their utility as mechanistic tools and their long-term therapeutic potential for a variety of human diseases. Here, we examine the ability of amphipathic isoxazolidines differing only in the placement of constituent side chains to function as transcriptional activation domains. The results reveal that precise positioning of functional groups within a conformationally constrained small molecule scaffold is not required for transcription function; rather, the balance of polarity and hydrophobicity within the scaffold is the more important determinant of transcription function. This suggests that a number of different organic …
Targeting The Transcriptional Machinery With Unique Artificial Transcriptional Activators, Brian Brennan, Zhiqian Wu, Garrette Belanger, Jenifer Lum, Aaron Minter, Steven Rowe, Annette Plachetka, Chinmay Majmudar, Anna Mapp
Targeting The Transcriptional Machinery With Unique Artificial Transcriptional Activators, Brian Brennan, Zhiqian Wu, Garrette Belanger, Jenifer Lum, Aaron Minter, Steven Rowe, Annette Plachetka, Chinmay Majmudar, Anna Mapp
Brian B. Brennan
The link between a growing number of human diseases and misregulation of gene expression has spurred intense interest in artificial transcriptional activators that could be used to restore controlled expression of affected genes. To expand the repertoire of activation domains available for the construction of artificial transcriptional regulators, a selection strategy was used to identify two unique activation domain motifs. These activation domains bear little sequence homology to endogenous counterparts and bind to unique sites within the transcriptional machinery. A comparison with two well-characterized activation domains, VP2 and P201, demonstrated for the first time that functional potency is not solely …